下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

超分子免疫调节水凝胶剂以持久内源性免疫增强 CAR-T 疗法实现实体瘤清除

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication.

平行处理 T 细胞与 NK 细胞以增强体内 CAR-T 细胞对血液肿瘤和实体瘤的活性

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

本研究鼓励优化利用白细胞单采产物。通过将废弃的 PBMC 回收为 NK 细胞，可有效增强 CAR-T 细胞疗法，改善肿瘤清除率和生存率。

CD70 靶向 HIT-CAR-T 细胞对乳腺癌患者来源异种移植瘤的控制

Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells.

探究共刺激结构域在增强三阴性乳腺癌中 CAR-T 细胞持久性中的作用

Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC.

嵌合抗原受体（CAR）T 细胞治疗在乳腺癌中的作用

The role of chimeric antigen receptor (CAR) T cell therapy in breast cancer.

微流控 Cytotongue 系统实现肿瘤球体中 CAR-T 诱导机械软化的早期无标记检测

Microfluidic Cytotongue system enables early, label-free detection of CAR-T-induced mechanical softening in tumor spheroids.

用于乳腺癌治疗的可注射水凝胶：从肿瘤微环境响应性与主动靶向药物递送到免疫治疗与诊疗一体化

Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran

利用免疫对抗乳腺癌：从检查点到细胞疗法

Harnessing immunity against breast cancer: from checkpoints to cell therapies.

低剂量多西他赛重编程 CAR-T 细胞以增强实体瘤免疫

Low-dose docetaxel reprograms CAR T cells for enhanced solid tumor immunity.

这些发现描述了一种非遗传药理学预激活策略，具有潜在的可扩展性并与现有生产工艺兼容。该方法在临床前模型中展示了增强的 CAR-T 细胞对抗实体瘤屏障的性能，突显了化疗-免疫治疗协同作用的潜力。